CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed at $71.08 in the latest trading session, marking a -0.74% move from the prior day. This change lagged the S&P 500's daily loss of 0.31%. At the same time, the Dow lost 0.41%, and the tech-heavy Nasdaq lost 0.27%.
Prior to today's trading, shares of the company had lost 14.74% over the past month. This has lagged the Medical sector's loss of 0.57% and the S&P 500's gain of 3.05% in that time.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.63 per share, which would represent a year-over-year decline of 143.28%. In the meantime, our current consensus estimate forecasts the revenue to be $8.31 million, indicating a 91.69% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$6.24 per share and a revenue of $105.41 million, indicating changes of -221.65% and -71.6%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 4.95% downward. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 83, placing it within the top 33% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
